Want to see AEMD full AI Analyst Report?
AEMD Stock Chart & Stats
$2.34
-$0.16(-18.80%)
At close: 4:00 PM EST
$2.34
-$0.16(-18.80%)
Day’s Range― - ―
52-Week Range$0.64 - $27.40
Previous CloseN/A
Volume1.62M
Average Volume (3M)688.41K
Market Cap
$1.86M
Enterprise Value-$3.24M
Total Cash (Recent Filing)$5.03M
Total Debt (Recent Filing)$336.72K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 12, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.89
Shares Outstanding2,633,560
10 Day Avg. Volume703,784
30 Day Avg. Volume688,413
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.96
Enterprise Value/Ebitda0.49
Forecast
1Y Price Target
$2.00Price Target Upside-14.53% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-2.21
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Progress: Cohort AdvancementDSMB clearance and initiation of Cohort 3 materially reduce near-term safety/regulatory risk and demonstrate operational ability to run multicohort studies. This durable progress strengthens the development pathway, supports future trial designs, and increases the probability of obtaining actionable clinical signals over the next several months.
Improved Expense DisciplineA sustained ~22% reduction in operating expenses and a ~46% improvement in net loss indicate management can materially lower burn. This improves runway per dollar raised and reduces recurring funding cadence, positively affecting capital needs and strategic optionality over a multi‑month horizon.
Device Compatibility Enabling Broader UseDemonstrated compatibility with a simplified pump supports use outside dialysis units and less invasive vascular access. Structurally, this can broaden potential treatment sites and physician adoption, improving scalability and commercial feasibility if clinical outcomes are confirmed in subsequent studies.
Bears Say
Modest Cash Vs. Ongoing BurnEnding cash plus recent ATM proceeds appear insufficient relative to annualized operating losses, implying a limited runway without further financing. This structural liquidity shortfall pressures program timelines, forces prioritization of activities, and constrains negotiation leverage with partners for the coming quarters.
Small, Non‑powered Efficacy StudyA small safety‑focused cohort (9–18 patients) cannot provide definitive efficacy evidence, meaning meaningful proof points will require larger, costlier trials. This extends development timelines, increases capital requirements, and leaves commercial prospects contingent on future, larger studies.
Ongoing Reliance On Equity FinancingsFrequent use of ATMs and follow‑on offerings signals dependence on external equity to fund operations. Structurally, that raises dilution risk for shareholders, can limit long‑term capital stability, and may force the company to raise at suboptimal times if internal cash generation remains limited.
Aethlon Medical News
AEMD FAQ
What was Aethlon Medical Inc’s price range in the past 12 months?
Aethlon Medical Inc lowest stock price was $0.64 and its highest was $27.40 in the past 12 months.
What is Aethlon Medical Inc’s market cap?
Aethlon Medical Inc’s market cap is $1.86M.
When is Aethlon Medical Inc’s upcoming earnings report date?
Aethlon Medical Inc’s upcoming earnings report date is Aug 12, 2026 which is in 29 days.
How were Aethlon Medical Inc’s earnings last quarter?
Aethlon Medical Inc released its earnings results on Jun 10, 2026. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of -$2.166 by $6.246.
Is Aethlon Medical Inc overvalued?
According to Wall Street analysts Aethlon Medical Inc’s price is currently Overvalued.
Does Aethlon Medical Inc pay dividends?
Aethlon Medical Inc does not currently pay dividends.
What is Aethlon Medical Inc’s EPS estimate?
Aethlon Medical Inc’s EPS estimate is -0.79.
How many shares outstanding does Aethlon Medical Inc have?
Aethlon Medical Inc has 2,633,560 shares outstanding.
What happened to Aethlon Medical Inc’s price movement after its last earnings report?
Aethlon Medical Inc reported an EPS of $4.08 in its last earnings report, beating expectations of -$2.166. Following the earnings report the stock price went down -5.941%.
Which hedge fund is a major shareholder of Aethlon Medical Inc?
Currently, no hedge funds are holding shares in AEMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aethlon Medical Inc
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
AEMD Stock 12 Month Forecast
Average Price Target
$2.00
▼(-14.53% Downside)
Technical Analysis
Ownership Overview
3.42% Insiders
0.26% Mutual Funds
1.08% Other Institutional Investors
95.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---